- Days
- Hours
- Minutes
- Seconds
About This Event
Despite significant advancements in drug development, classical drug discovery is still unable to target more than 75% of proteins. Target protein degraders (TPDs) can target intracellular proteins through modified cellular protein degradation mechanisms, and will transform treatments in oncology and other indications in the coming decades.
TPDs are garnering interest and their potential is substantial.
Join us to unravel the potential of TPDs in oncology and other therapeutic areas with focus on -
- How will the landscape of TPDs development look in the coming decade?
- What are the unique challenges associated with TPD development?
- Beyond oncology where can TPDs prove to be effective treatments?
- How will potential emergence of TPDs impact treatments options for patients with cancer and other diseases?
- How impactful can TPDs be in neurodegeneration, immune disorders, and infectious diseases etc?
Register Now
Our Panel of Forward-thinking Industry Experts
Dr. Ankita Malik
Ankita is a Ph.D in molecular biology. She has deep expertise in oncology business research and consulting, R&D strategy, and competitive and treatment landscapes for companies developing oncology assets.
Dr. Shivali Jasrotia
With rich experience in oncology consulting, Shivali excels in strategic and evidence-based solutions, covering portfolio analysis, opportunity prioritization, and product development.